Protection from apoptotic cell death by cilostazol, phosphodiesterase type III inhibitor, via cAMP-dependent protein kinase activation

Pharmacological Research

Volumn 54, Issue 4, 2006, Pages 261-267

  Kim, Mi Jeong ^a,b   Lee, Jeong Hyun ^a   Park, So Youn ^a   Hong, Ki Whan ^a,c   Kim, Chi Dae ^a,c   Kim, Ki Young ^d   Lee, Won Suk ^a,c  

^a Pusan National University School of Medicine   (South Korea)

^b Yangsan Neuropsychiatric Hospital   (South Korea)

^c Pusan National University   (South Korea)

^d Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Apoptosis; cAMP dependent protein kinase; Cilostazol; Human umbilical vein endothelial cells

Indexed keywords

BUCLADESINE; CILOSTAMIDE; CILOSTAZOL; CYCLIC AMP DEPENDENT PROTEIN KINASE; DEHYDROCILOSTAZOL; DNA FRAGMENT; DRUG METABOLITE; LIPOPOLYSACCHARIDE; OPC 31213; PHOSPHODIESTERASE III INHIBITOR; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AGAR GEL ELECTROPHORESIS; APOPTOSIS; ARTICLE; CELL AGGREGATION; CELL DEATH; CELL STIMULATION; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; UMBILICAL VEIN;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; BUCLADESINE; CELL LINE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DNA FRAGMENTATION; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HUMANS; LIPOPOLYSACCHARIDES; PHOSPHODIESTERASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; TETRAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33747183132     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.05.006     Document Type: Article

References (27)

1. Kimura Y., Tani T., Kanbe T., and Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35 (1985) 1144-1149
2. Katakami Y., Nakao Y., Koizumi T., Katakami N., Ogawa R., and Fujita T. Regulation of tumor necrosis factor production by mouse peritoneal macrophages: the role of cellular cyclic AMP. Immunology 64 (1988) 719-724
3. Dawson D.L., Cutler B.S., Meissner M.H., and Strandness Jr. D.E. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 98 (1998) 678-686
4. Gotoh F., Tohgi H., Hirai S., Terashi A., Fukuuchi Y., Otomo E., et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 9 (2000) 147-157
5. Mantovani A., and Dejana E. Cytokines as communication signals between leukocytes and endothelial cells. Immunol Today 10 (1989) 370-375
6. Varani J., and Ward P.A. Mechanisms of endothelial cell injury in acute inflammation. Shock 2 (1994) 311-319
7. Beutler B., and Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem 57 (1988) 505-518
8. Knoblach S.M., Fan L., and Faden A.I. Early neuronal expression of tumor necrosis factor-α after experimental brain injury contributes to neurological impairment. J Neuroimmunol 95 (1999) 115-125
9. Nagata S. Apoptosis by death factor. Cell 88 (1997) 355-365
10. Koga S., Morris S., Ogawa S., Liao H., Bilezikkian J.P., Chen G., et al. TNF modulates endothelial properties by decreasing cAMP. Am J Physiol 268 (1995) C1104-C1113
11. Yang E., and Korsmeyer S.J. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 88 (1996) 386-401
12. Tsujimoto Y., and Croce C.M. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83 (1986) 5214-5218
13. Chen J., Graham S.H., Nakayama M., Zhu R.L., Jin K., Stetler R.A., et al. Apoptosis repressor genes Bcl-2 and Bcl-x-long are expressed in the rat brain following global ischemia. J Cereb Blood Flow Metab 17 (1997) 2-10
14. Davies A.M., Martin E.A., Jones R.M., Lim C.K., Smith L.L., and White I.N. Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts. Carcinogenesis 16 (1995) 539-545
15. Wyllie A.H., Kerr J.F., and Currie A.R. Cell death: the significance of apoptosis. Int Rev Cytol 68 (1980) 251-306
16. Kim K.Y., Shin H.K., Choi J.M., and Hong K.W. Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 300 (2002) 709-715
17. Old L.J. Tumor necrosis factor (TNF). Science 230 (1985) 630-632
18. Egido J., Gomez-Chiarri M., Ortiz A., Bustos C., Alonso J., Gomez Guerrero C., et al. Role of tumor necrosis factor-α in the pathogenesis of glomerular diseases. Kidney Int 43 (1993) S59-S64
19. Böhler T., Waiser J., Hepburn H., Gaedeke J., Lehmann C., Hambach P., et al. TNF-α and IL-1α induce apoptosis in subconfluent rat mesangial cells. Evidence for the involvement of hydrogen peroxide and lipid peroxidation as second messengers. Cytokine 12 (2000) 986-991
20. Kochanek P.M., and Hallenbeck J.M. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 23 (1992) 1367-1379
21. Kroemer G., Petit P., Zamzami N., Vayssiere J.L., and Mignotte B. The biochemistry of programmed cell death. FASEB J 9 (1995) 1277-1287
22. Kane D.J., Sarafian T.A., Anton R., Hahn H., Butler Gralla E., Valentine J.S., et al. Bcl-2 inhibition of neutral death: decreased generation of reactive oxygen species. Science 262 (1993) 1274-1277
23. Hockenbery D.M. Bcl-2, a novel regulator of cell death. Bioassays 17 (1995) 631-638
24. Li P.F., Dietz R., and von Harsdorf R. Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of vascular smooth muscle cells. Circulation 96 (1997) 3602-3609
25. Oltvai Z., Milliman C., and Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74 (1993) 609-619
26. Choi J.M., Shin H.K., Kim K.Y., Lee J.H., and Hong K.W. Neuroprotective effect of cilostazol against focal cerebral ischemia via anti-apoptotic action in rats. J Pharmacol Exp Ther 300 (2002) 787-793
27. Lee J.H., Oh G.T., Park S.Y., Choi J.H., Park J.G., Kim C.D., et al. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-α formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 313 (2005) 502-509